More information: Adonis Rubio et al, Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern, Science Translational Medicine ...

Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern.

Scientists have identified a new pair of antibodies that could fend off multiple COVID-19 variants. Found in people who successfully recovered from the illness, these antibodies attach to a part ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution ...

ProMIS Neurosciences (PMN) announced plans to deliver virtual oral presentations at the 2025 Alzheimer’s and Parkison’s Disease International ...

This enzymatic method enables highly specific and complete 1:1 protein conjugations with small molecules, solid supports, and other proteins, offering broad applicability across diverse biochemical ...

This area, within the Spike N-terminal domain, or NTD, had been overlooked because it was not directly useful for treatment. However, when a specific antibody attaches to this area, it remains ...

The bispecific antibodies target two areas of the virus: One attaches to the NTD (spike N-terminal domain), an area on the virus that does not change very much. This allows the second antibody to ...